{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:15:10Z","timestamp":1789089310226,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA210961"],"award-info":[{"award-number":["P01CA210961"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA280970"],"award-info":[{"award-number":["R01CA280970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>I-SPY2 is a long-running phase 2 platform trial that evaluates neoadjuvant treatments for locally advanced breast cancer to identify those with high efficacy that are likely to be successful in phase 3 trials, assigning patients to novel agents using response-adaptive randomization (RAR). Recently, I-SPY2 was reconfigured as a sequential multiple assignment randomized trial (SMART), with up to three stages of therapy. At the first stage, a patient is assigned to a tumor-subtype-specific therapy. If the patient fails to show a satisfactory response, the patient is assigned to a second subtype-specific therapy, and receives a third, rescue therapy if response is still not achieved. The I-SPY2 SMART thus supports identification of highly efficacious entire treatment regimes. The transition of I-SPY2 to a SMART required development of a RAR scheme that updates randomization probabilities at each stage, aligned with the goal of maximizing the number of patients who achieve a pathological complete response (pCR). We present our Bayesian RAR approach, which updates randomization probabilities based on the posterior probability that treatments are part of the optimal regime. Empirical studies demonstrate that it results in more patients having treatment experience consistent with highly efficacious regimes, improves overall within-trial pCR rates, and identifies optimal regimes post trial at rates similar to or exceeding those under simple, uniform, nonadaptive randomization.<\/jats:p>","DOI":"10.1093\/biomtc\/ujag063","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:49:19Z","timestamp":1774702159000},"source":"Crossref","is-referenced-by-count":1,"title":["Bayesian adaptive randomization in the I-SPY2 sequential multiple assignment randomized trial"],"prefix":"10.1093","volume":"82","author":[{"given":"Peter","family":"Norwood","sequence":"first","affiliation":[{"name":"Quantum Leap Healthcare Collaborative , San Francisco, CA 94104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[{"name":"University of California Department of Surgery, , San Francisco, San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wolf","sequence":"additional","affiliation":[{"name":"University of California Department of Surgery, , San Francisco, San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beineke","sequence":"additional","affiliation":[{"name":"Quantum Leap Healthcare Collaborative , San Francisco, CA 94104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chapple","sequence":"additional","affiliation":[{"name":"Quantum Leap Healthcare Collaborative , San Francisco, CA 94104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Tsiatis","sequence":"additional","affiliation":[{"name":"North Carolina State University Department of Statistics, , Raleigh, NC 27695-8203 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9202-6341","authenticated-orcid":false,"given":"Marie","family":"Davidian","sequence":"additional","affiliation":[{"name":"North Carolina State University Department of Statistics, , Raleigh, NC 27695-8203 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026051804114874900_bib1","doi-asserted-by":"crossref","DOI":"10.1201\/b16101","volume-title":"Randomised Response-Adaptive Designs in Clinical Trials","author":"Atkinson","year":"2013"},{"key":"2026051804114874900_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.2010.32.2685","article-title":"Adaptive clinical trials: the promise and the caution","volume":"29","author":"Berry","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"2026051804114874900_bib3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.molonc.2015.02.011","article-title":"The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research","volume":"9","author":"Berry","year":"2015","journal-title":"Molecular Oncology"},{"key":"2026051804114874900_bib4","doi-asserted-by":"crossref","DOI":"10.1201\/EBK1439825488","volume-title":"Bayesian Adaptive Methods for Clinical Trials","author":"Berry","year":"2010"},{"key":"2026051804114874900_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/biom.12258","article-title":"Sequential multiple assignment randomized trial (SMART) with adaptive randomization for quality improvement in depression treatment program","volume":"71","author":"Cheung","year":"2015","journal-title":"Biometrics."},{"key":"2026051804114874900_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cct.2017.09.002","article-title":"Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program","volume":"62","author":"Das","year":"2017","journal-title":"Contemporary Clinical Trials"},{"key":"2026051804114874900_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/047005588X","volume-title":"The Theory of Response-Adaptive Randomization in Clinical Trials","author":"Hu","year":"2006"},{"key":"2026051804114874900_bib8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathological complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: Three-year follow-up analysis for the I-SPY2 adpatively randomized clinical trial","volume":"6","author":"I-SPY2 Trial Consortium","year":"2020","journal-title":"JAMA Oncology"},{"key":"2026051804114874900_bib9","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03266-2","article-title":"Datopotamab\u2013deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Khoury","year":"2024","journal-title":"Nature Medicine"},{"key":"2026051804114874900_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.2010.31.1423","article-title":"Outcome-adaptive randomization: Is it useful?","volume":"29","author":"Korn","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"2026051804114874900_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1191\/1740774504cn002oa","article-title":"Dynamic treatment regimes: practical design considerations","volume":"1","author":"Lavori","year":"2004","journal-title":"Clinical Trials"},{"key":"2026051804114874900_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12910-015-0022-z","article-title":"Clinical trialist perspectives on the ethics of adaptive clinical trials: A mixed-methods analysis","volume":"16","author":"Legocki","year":"2015","journal-title":"BMC Medical Ethics"},{"key":"2026051804114874900_bib13","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/sim.2022","article-title":"An experimental design for the development of adaptive treatment strategies","volume":"24","author":"Murphy","year":"2005","journal-title":"Statistics in Medicine"},{"key":"2026051804114874900_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncology"},{"key":"2026051804114874900_bib15","doi-asserted-by":"crossref","first-page":"ujae152","DOI":"10.1093\/biomtc\/ujae152","article-title":"Adaptive randomization methods for sequential multiple assignment randomized trials (SMARTs) via Thompson sampling","volume":"80","author":"Norwood","year":"2024","journal-title":"Biometrics."},{"key":"2026051804114874900_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-3-031-64350-7_80","article-title":"CARA randomization: Optimality, inference, enrichment","volume-title":"Methodological and Applied Statistics and Demography II","author":"Rosenberger","year":"2025"},{"key":"2026051804114874900_bib17","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nature Medicine"},{"key":"2026051804114874900_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ejca.2007.01.006","article-title":"Practical Bayesian adaptive randomization in clinical trials","volume":"43","author":"Thall","year":"2007","journal-title":"European Journal of Cancer"},{"key":"2026051804114874900_bib19","first-page":"287","article-title":"Some caveats for outcome adaptive randomization in clinical trials","volume-title":"Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects.","author":"Thall","year":"2015"},{"key":"2026051804114874900_bib20","volume-title":"Dynamic Treatment Regimes: Statistical Methods for Precision Medicine","author":"Tsiatis","year":"2020"},{"key":"2026051804114874900_bib21","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/biostatistics\/kxab020","article-title":"Adaptive randomization in a two-stage sequential multiple assignment randomized trial","volume":"23","author":"Wang","year":"2022","journal-title":"Biostatistics (Oxford, England)"},{"key":"2026051804114874900_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1740774517692302","article-title":"A simulation study of outcome adaptive randomization in multi-arm clinical trials","volume":"14","author":"Wathen","year":"2017","journal-title":"Clinical Trials"},{"key":"2026051804114874900_bib23","doi-asserted-by":"crossref","first-page":"ujae073","DOI":"10.1093\/biomtc\/ujae073","article-title":"A generalized outcome-adaptive sequential multiple assignment randomized trial design","volume":"80","author":"Yang","year":"2024","journal-title":"Biometrics."},{"key":"2026051804114874900_bib24","first-page":"7460","article-title":"Statistical inference with M-estimators on adaptively collected data","volume":"34","author":"Zhang","year":"2021","journal-title":"Advances in Neural Information Processing Systems"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/2\/ujag063\/68185268\/ujag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/2\/ujag063\/68185268\/ujag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:12:21Z","timestamp":1779091941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/doi\/10.1093\/biomtc\/ujag063\/8664726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1093\/biomtc\/ujag063","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,9]]},"article-number":"ujag063"}}